Malta - English - Medicines Authority

pinewood laboratories limited ballymacarbry, clonmel, co. tipperary, ireland - ondansetron hydrochloride, dihydrate - film-coated tablet - ondansetron hydrochloride dihydrate 4 mg - antiemetics and antinauseants

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - ondansetron hydrochloride -

United Kingdom - English - myHealthbox

syri limited - ondansetron hydrochloride dihydrate - syrup - 4mg/5ml - antiemetics and antinauseants, serotonin (5ht3) antagonist - ondansetron syrup is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. ondansetron syrup is also indicated for the prevention of post-operative nausea and vomiting (ponv).

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - ondansetron hydrochloride dihydrate 2.5 mg/ml equivalent to ondansetron 2 mg/ml;   - solution for injection - 2 mg/ml - active: ondansetron hydrochloride dihydrate 2.5 mg/ml equivalent to ondansetron 2 mg/ml   excipient: citric acid monohydrate sodium chloride sodium citrate dihydrate water for injection - ondansetron injection is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. ondansetron injection is also indicated for the prevention and treatment of post-operative nausea and vomiting.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - ondansetron hydrochloride dihydrate, quantity: 10 mg (equivalent: ondansetron, qty 8 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; sodium starch glycollate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 400 - prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy.

Canada - English - Health Canada

sandoz canada incorporated - ondansetron (ondansetron hydrochloride dihydrate) - solution - 2mg - ondansetron (ondansetron hydrochloride dihydrate) 2mg - 5-ht3 receptor antagonists

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories limited - ondansetron hydrochloride (unii: nmh84ozk2b) (ondansetron - unii:4af302esos) - tablet, film coated - 16 mg - ondansetron   tablets are indicated for the prevention of nausea and vomiting associated with: - highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m2 . highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m2 . - initial and repeat courses of moderately emetogenic cancer chemotherapy. initial and repeat courses of moderately emetogenic cancer chemotherapy. - radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen ondansetron tablets are also indicated for the prevention of postoperative nausea and/or vomiting. ondansetron is contraindicated in patients: - known to have hypersensitivity (e.g., anaphylaxis) to ondansetron or any of the components of the formulation [see adverse reactions (6.2)] - receiving co

United States - English - NLM (National Library of Medicine)

h.j. harkins company, inc. - ondansetron hydrochloride (unii: nmh84ozk2b) (ondansetron - unii:4af302esos) - ondansetron 4 mg - - prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥50 mg/m2 . - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. - prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. - prevention of postoperative nausea and/or vomiting. as with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided postoperatively, ondansetron hydrochloride tablets are recommended even where the incidence of postoperative nausea and/or vomiting is low. ondansetron hydrochloride tablets are contraindicated for patients known to have hypersensitivity to the drug. animal studies have shown that ondansetron is no

United States - English - NLM (National Library of Medicine)

stat rx usa - ondansetron (unii: 4af302esos) (ondansetron - unii:4af302esos) - ondansetron 4 mg - - prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥50 mg/m2 . - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. - prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. - prevention of postoperative nausea and/or vomiting. as with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided postoperatively, ondansetron hydrochloride tablets and ondansetron orally disintegrating tablets are recommended even where the incidence of postoperative nausea and/or vomiting is low. ondansetron hydrochloride tablets and ondansetron orally disintegrating tablets are contraindicated fo

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - ondansetron hydrochloride (unii: nmh84ozk2b) (ondansetron - unii:4af302esos) - ondansetron 4 mg - prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥ 50 mg/m2. prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. prevention of postoperative nausea and/or vomiting. as with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided postoperatively, ondansetron tablets are recommended even where the incidence of postoperative nausea and/or vomiting is low. the concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and loss of consciousness when apomorphine was adminis